BerGenBio ASA (OSL:BGBIO)
Norway flag Norway · Delayed Price · Currency is NOK
1.832
-0.098 (-5.08%)
May 30, 2025, 4:25 PM CET

BerGenBio ASA Company Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway.

The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and BGBIL025, a JAK2 inhibitor, which is in preclinical stage for treatment of the bone marrow disorder myelofibrosis.

BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.

BerGenBio ASA
BerGenBio ASA logo
Country Norway
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Olav Hellebo

Contact Details

Address:
Nygardsgaten 114
Bergen, 5008
Norway
Phone 47 55 96 11 59
Website bergenbio.com

Stock Details

Ticker Symbol BGBIO
Exchange Oslo Børs
Fiscal Year January - December
Reporting Currency NOK
ISIN Number NO0010650013
SIC Code 2836

Key Executives

Name Position
Olav Hellebo BBA, MBA Chief Executive Officer
Rune Skeie Chief Financial Officer
Cristina Oliva M.D. Chief Medical Officer
Graham Morell Head of IR
Gayle M. Mills M.B.A Chief Business Officer
Dr. Akil Jackson Medical Director